At the threshold of clinical trials:The status of the Finnish BNCT project

Autor: Färkkilä, Markus, Savolainen, Sauli, Kallio, Merja, Auterinen, Iiro, Kulvik, Martti, Hiismäki, Pekka, Snellman, Marjatta, Aschan, Carita, Benczik, Judit, Jääskeläinen, Juha, Järviluoma, Eija, Joensuu, Heikki, Kankaanranta, Leena, Kortesniemi, Mika, Kosunen, Antti, Kotiluoto, Petri, Laakso, Juha, Pakkala, Seppo, Rasilainen, Merja, Salmenhaara, Seppo, Seppälä, Tiina, Serén, Tom, Suominen, Marika, Tenhunen, Mikko, Toivonen, Matti, Tähtinen, Leena, Vähätalo, Jyrki

Publikováno v: Färkkilä, M, Savolainen, S, Kallio, M, Auterinen, I, Kulvik, M, Hiismäki, P, Snellman, M, Aschan, C, Benczik, J, Jääskeläinen, J, Järviluoma, E, Joensuu, H, Kankaanranta, L, Kortesniemi, M, Kosunen, A, Kotiluoto, P, Laakso, J, Pakkala, S, Rasilainen, M, Salmenhaara, S, Seppälä, T, Serén, T, Suominen, M, Tenhunen, M, Toivonen, M, Tähtinen, L & Vähätalo, J 2001, At the threshold of clinical trials : The status of the Finnish BNCT project . in M F Hawthorne, K Shelly & R J Wiersema (eds), Frontiers in Neutron Capture Therapy . vol. 1, Springer, pp. 129-131, 8th International Symposium on Neutron Capture Therapy for Cancer, Los Angeles, California, United States, 13/08/98 . https://doi.org/10.1007/978-1-4615-1285-1_14

The aim of the Finnish BNCT-project is to start BNC-treatments of malignant brain tumors. The first clinical trial is planned to start in early 1999 at the treatment facility of the 250kW FiR 1 TRIGA research reactor. Excellent patient treatment faci

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=355e65625b88::4437a6bcc7f6d13baa97f70e94f04f2e
https://cris.vtt.fi/en/publications/df0a0bd8-3a8f-41be-a842-4b3ba4b66363

Gene expression analysis of 1,25(OH)2 D3 -dependent differentiation of HL-60 cells: a cDNA array study.

Autor: Savli, Hakan, Aalto, Yan, Nagy, Bálint, Knuutila, Sakari, Pakkala, Seppo

Publikováno v: British Journal of Haematology; Sep2002, Vol. 118 Issue 4, p1065-1070, 6p

Increased serum neutral endopeptidase activity in acute renal allograft rejection.

Autor: Tikkanen, Ilkka, Salmela, Kaija, Hohenthal, Ulla, Teppo, Anna-Maija, Pakkala, Seppo, Ahonen, Juhani, Fyhrquist, Frej, Tikkanen, I, Salmela, K, Hohenthal, U, Teppo, A M, Pakkala, S, Ahonen, J, Fyhrquist, F

Publikováno v: American Journal of Nephrology; 1996, Vol. 16 Issue 4, p273-279, 7p

Decreasing CD4/CD8 Ratio During Prolonged Four-Drug Chemotherapy plus Interferon Treatment for Metastatic Melanoma.

Autor: Muhonen, Timo, Hahka-Kemppinen, Marjo, Pakkala, Seppo, Pyrhönen, Seppo

Publikováno v: Journal of Immunotherapy; Jan1994, Vol. 15 Issue 1, p67-73, 7p

A VITAMIN D ANALOG, MC1288, INHIBITS ADVENTITIAL INFLAMMATION AND SUPPRESSES INTIMAL LESIONS IN RAT AORTIC ALLOGRAFTS.

Autor: Räisänen-Sokolowski, Anne K., Pakkala, Ilkka S., Samila, Sampsa P., Binderup, Lise, Häyry, Pekka J., Pakkala, Seppo T.

Publikováno v: Transplantation; Apr1997, Vol. 63 Issue 7, p936-941, 6p